Drug industry heavyweights: Research cuts threaten U.S.

03/6/2013 | Forbes

Public funding of agencies that support scientific and biomedical research pays significant dividends and should be restored immediately, write former Genentech CSO Marc Tessier-Lavigne, Regeneron Pharmaceuticals Chairman P. Roy Vagelos and former NIH Director and Sanofi R&D President Elias Zerhouni. Great strides have been made in cardiovascular and HIV/AIDS research thanks to NIH funding, but Alzheimer's disease, diabetes and other chronic diseases threaten to break the nation's bank in the absence of investments in research, they write. Even before sequestration, steadily eroding funds squeezed research and sent many U.S. scientists abroad, harming U.S. competitiveness, they write.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN